Aptevo Therapeutics Secures Millions in Cash Through Heavily Dilutive Stock Deal

Seattle, Wednesday, 11 November 2026.
To secure $3 million in immediate capital, Aptevo agreed to issue nearly 14 million new purchase rights, significantly expanding future shares while funding its cancer drug pipeline.